Clene (CLNN) vs Mereo BioPharma Group (MREO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Clene (CLNN) has outperformed Mereo BioPharma Group (MREO) over the past year, losing 58.8% versus a loss of 80.9%. Over five years, MREO leads with a -82.8% price change compared with -96.9% for CLNN. Mereo BioPharma Group is the larger company by market cap ($56.8 million vs $55.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLNN | MREO |
|---|---|---|
| Share price | $3.88 | $0.3556 |
| Market cap | $55.15M | $56.79M |
| 1-day change | 0.00% | -5.22% |
| YTD return | -33.90% | -10.02% |
| 1-year return | -58.81% | -80.86% |
| 5-year return | -96.86% | -82.79% |
| EPS (TTM) | $-3.52 | $-0.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $13.50 | $2.37 |
| 52-week low | $3.25 | $0.20 |
| Distance from 52-week high | -71.26% | -85.00% |
| Analyst consensus | none | none |
| Avg. price target upside | +729.90% | +451.18% |
| Average volume | 100.21K | 4.04M |
| Shares outstanding | 14.21M | 159.69M |
| Employees | 76 | 39 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CLNN has outperformed MREO by 22.0 percentage points over the past year.
About Clene
CLNN stock →Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees
About Mereo BioPharma Group
MREO stock →Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of rare diseases in the United Kingdom and the United States. The company develops Setrusumab, an antibody for the treatment of osteogenesis imperfecta; Alvelestat, an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency associated lung disease; and Vantictumab, an anti-FZD monoclonal antibody for the treatment of autosomal dominant osteopetrosis type 2.
Health Care · Biotechnology: Pharmaceutical Preparations · 39 employees
CLNN vs MREO FAQ
Which is bigger, Clene or Mereo BioPharma Group?
Mereo BioPharma Group (MREO) is larger, with a market capitalization of $56.79M compared with $55.15M for Clene (CLNN).
Which stock has performed better over the past year, CLNN or MREO?
CLNN returned -58.81% over the past 12 months, compared with -80.86% for MREO (price return, excluding dividends). Past performance does not predict future results.
Are Clene and Mereo BioPharma Group in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.